• Explore /
  • Poster
  • / Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase II trial.

Toripalimab plus axitinib versus toripalimab or axitinib alone in patients with treatment-naive unresectable or metastatic mucosal melanoma: Interim results from a randomized, controlled, phase II trial.

Abstract Poster

Authors

null

Chuanliang Cui

Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China

Chuanliang Cui , BIN LIAN , Xinan Sheng , Huayan Xu , Lu Si , Zhihong Chi , Yue Yang , Xuan Wang , Caili Li , Lili Mao , Bixia Tang , Xieqiao Yan , Siming Li , Xue Bai , Li Zhou , Xiaoting Wei , Juan Li , Rong Duan , Jun Guo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Melanoma/Skin Cancers

Track

Melanoma/Skin Cancers

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT03941795

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9512)

DOI

10.1200/JCO.2022.40.16_suppl.9512

Abstract #

9512

Poster Bd #

106

Abstract Disclosures

Similar Posters

First Author: Xiangrui Meng

First Author: Renata Ferrarotto

First Author: Inna Markovna Chen

First Author: Deborah J.L. Wong